The Experts below are selected from a list of 12678 Experts worldwide ranked by ideXlab platform
Gary S. Figiel - One of the best experts on this subject based on the ideXlab platform.
-
Mild Senile Dementia of the Alzheimer type. 4. Evaluation of intervention.
Annals of neurology, 1992Co-Authors: Leonard Berg, J. Philip Miller, Jack Baty, Eugene H. Rubin, John C. Morris, Gary S. FigielAbstract:The design of trials of interventions intended to slow or arrest the progression of Senile Dementia of the Alzheimer type must be based on analysis of the natural hisotry of the disease. Using a random coefficients statistical model, we analyzed the natural hisotry of Senile Dementia of the Alzheimer type in carefully defined subjects with milde disease (n = 68) for periods of up to 10 years. Subject performance was assessed longitudinally on batteries of clinical and psychometric measures. The characteristics of these measures were analyzed relevant to their utility as outcome measures for long-term trials in patients with Senile Dementia of the Alzheimer type. Estimates were made of sample sizes required to show arrest, and 50% or 25% slowing in the progression of mild disease. We suggest that a clinically relevant global measure, such as the Sum of Boxes of the Clinical Dementia Rating scale, and a performance-based clinical scale or psychometric measure would be appropriate in a 12- or 24-month trial enrolling subjects with mild Senile Dementia of the Alzheimer type.
Karen Ritchie - One of the best experts on this subject based on the ideXlab platform.
-
Progressive disability in Senile Dementia is accelerated in the presence of depression.
International journal of geriatric psychiatry, 1998Co-Authors: Karen Ritchie, Jacques Touchon, Bernard LedésertAbstract:Objectives. To assess the extent to which loss of ability to perform everyday activities in early stage Senile Dementia is worsened by the presence of depressive illness. Methods. The evolution of disabilities is measured by an activity scale permitting observation of small changes in everyday performance in a cohort of 397 elderly persons with subclinical cognitive deficit. Over the 3 years of the study, 11% of the cohort developed Dementia without depression and 5% Dementia with depression. Results. Progressive disablement was found to be greater in persons with Senile Dementia as compared to normal subjects. Depression alone had no significant effect over the time period. Persons with both Senile Dementia and depression had significantly higher rates of disability at 3 years than persons with Senile Dementia alone. Significantly greater decrements across the observation period were observed in dressing, washing, use of telephone and continence in the Senile Dementia–depression group only. Conclusion. Depression does not in itself engender significant disability but interacts with Senile Dementia to accelerate loss of functioning. Effective treatment of depressive illness in Senile Dementia may have significant impact on the prevalence and severity of disability. © 1998 John Wiley & Sons, Ltd.
-
The relationship between age and the prevalence of Senile Dementia: a meta-analysis of recent data.
International journal of epidemiology, 1992Co-Authors: Karen Ritchie, Daniel Kildea, Jean-marie RobineAbstract:A linear regression model derived from a meta-analysis of 13 epidemiological studies of Senile Dementia conducted since 1980, and employing internationally-known case-finding procedures, suggests a much lower general rate of Dementia prevalence than has been previously estimated. An exponential increase with age is observed, with Senile Dementia prevalence diagnosed by Diagnostic and Statistical Manual (DSM-III) criteria doubling every 6 years and Senile Dementia of the Alzheimer's type (SDAT) every 4.2 years. Studies providing data for the oldest ages indicating a drop in the rate of increase after the age of 80 suggest that Senile Dementia may be age-related rather than ageing-related. Estimates derived from this model may provide a reasonably accurate means of estimating Dementia prevalence in the general population. The limitations of this method for the purposes of prediction and studies of risk factors are discussed in relation to the hypothesized heterogeneity of Senile Dementia and possible cohort effects.
Jean-marie Robine - One of the best experts on this subject based on the ideXlab platform.
-
The relationship between age and the prevalence of Senile Dementia: a meta-analysis of recent data.
International journal of epidemiology, 1992Co-Authors: Karen Ritchie, Daniel Kildea, Jean-marie RobineAbstract:A linear regression model derived from a meta-analysis of 13 epidemiological studies of Senile Dementia conducted since 1980, and employing internationally-known case-finding procedures, suggests a much lower general rate of Dementia prevalence than has been previously estimated. An exponential increase with age is observed, with Senile Dementia prevalence diagnosed by Diagnostic and Statistical Manual (DSM-III) criteria doubling every 6 years and Senile Dementia of the Alzheimer's type (SDAT) every 4.2 years. Studies providing data for the oldest ages indicating a drop in the rate of increase after the age of 80 suggest that Senile Dementia may be age-related rather than ageing-related. Estimates derived from this model may provide a reasonably accurate means of estimating Dementia prevalence in the general population. The limitations of this method for the purposes of prediction and studies of risk factors are discussed in relation to the hypothesized heterogeneity of Senile Dementia and possible cohort effects.
Leonard Berg - One of the best experts on this subject based on the ideXlab platform.
-
Mild Senile Dementia of the Alzheimer type. 4. Evaluation of intervention.
Annals of neurology, 1992Co-Authors: Leonard Berg, J. Philip Miller, Jack Baty, Eugene H. Rubin, John C. Morris, Gary S. FigielAbstract:The design of trials of interventions intended to slow or arrest the progression of Senile Dementia of the Alzheimer type must be based on analysis of the natural hisotry of the disease. Using a random coefficients statistical model, we analyzed the natural hisotry of Senile Dementia of the Alzheimer type in carefully defined subjects with milde disease (n = 68) for periods of up to 10 years. Subject performance was assessed longitudinally on batteries of clinical and psychometric measures. The characteristics of these measures were analyzed relevant to their utility as outcome measures for long-term trials in patients with Senile Dementia of the Alzheimer type. Estimates were made of sample sizes required to show arrest, and 50% or 25% slowing in the progression of mild disease. We suggest that a clinically relevant global measure, such as the Sum of Boxes of the Clinical Dementia Rating scale, and a performance-based clinical scale or psychometric measure would be appropriate in a 12- or 24-month trial enrolling subjects with mild Senile Dementia of the Alzheimer type.
Eugene H. Rubin - One of the best experts on this subject based on the ideXlab platform.
-
Mild Senile Dementia of the Alzheimer type. 4. Evaluation of intervention.
Annals of neurology, 1992Co-Authors: Leonard Berg, J. Philip Miller, Jack Baty, Eugene H. Rubin, John C. Morris, Gary S. FigielAbstract:The design of trials of interventions intended to slow or arrest the progression of Senile Dementia of the Alzheimer type must be based on analysis of the natural hisotry of the disease. Using a random coefficients statistical model, we analyzed the natural hisotry of Senile Dementia of the Alzheimer type in carefully defined subjects with milde disease (n = 68) for periods of up to 10 years. Subject performance was assessed longitudinally on batteries of clinical and psychometric measures. The characteristics of these measures were analyzed relevant to their utility as outcome measures for long-term trials in patients with Senile Dementia of the Alzheimer type. Estimates were made of sample sizes required to show arrest, and 50% or 25% slowing in the progression of mild disease. We suggest that a clinically relevant global measure, such as the Sum of Boxes of the Clinical Dementia Rating scale, and a performance-based clinical scale or psychometric measure would be appropriate in a 12- or 24-month trial enrolling subjects with mild Senile Dementia of the Alzheimer type.
